Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Public ClinicalTrials.gov record NCT04445987. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Open-Label Study of the Long-Term Safety of ARQ-154 Foam 0.3% in Subjects With Seborrheic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0.3% in subjects with seborrheic dermatitis involving up to 20% total Body Surface Area (BSA). Study was applied topically once daily for 52 weeks. Cohort 1 subjects are rollover subjects from study ARQ-154-203 (NCT04091646) and were rolled into treatment in the current study without interruption. Cohort 2 includes participants from ARQ-154-203 who began treatment in the current study after a gap from completing treatment in the prior study.
Study identification
- NCT ID
- NCT04445987
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 408 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 9 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 12, 2020 (Actual)
- Primary completion
- Nov 19, 2022 (Actual)
- Completion
- Nov 19, 2022 (Actual)
- Last update posted
- Jun 11, 2024
2020 – 2022
United States locations
- U.S. sites
- 39
- U.S. states
- 20
- U.S. cities
- 39
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arcutis Biotherapeutics Clinical Site 59 | Beverly Hills | California | 90212 | — |
| Arcutis Biotherapeutics Clinical Site 51 | Encino | California | 91436 | — |
| Arcutis Biotherapeutics Clinical Site 75 | Fountain Valley | California | 92708 | — |
| Arcutis Biotherapeutics Clinical Site 19 | Fremont | California | 94538 | — |
| Arcutis Biotherapeutics Clinical Site 62 | Los Angeles | California | 90036 | — |
| Arcutis Biotherapeutics Clinical Site 64 | San Diego | California | 92123 | — |
| Arcutis Biotherapeutics Clinical Site 21 | Santa Monica | California | 90404 | — |
| Arcutis Biotherapeutics Clinical Site 53 | Aventura | Florida | 33180 | — |
| Arcutis Biotherapeutics Clinical Site 42 | Coral Gables | Florida | 33134 | — |
| Arcutis Biotherapeutics Clinical Site 57 | Delray Beach | Florida | 33484 | — |
| Arcutis Biotherapeutics Clinical Site 24 | Miami | Florida | 33144 | — |
| Arcutis Biotherapeutics Clinical Site 65 | Sanford | Florida | 32771 | — |
| Arcutis Biotherapeutics Clinical Site 12 | Tampa | Florida | 33613 | — |
| Arcutis Biotherapeutics Clinical Site 10 | Rolling Meadows | Illinois | 60008 | — |
| Arcutis Biotherapeutics Clinical Site 22 | Plainfield | Indiana | 46168 | — |
| Arcutis Biotherapeutics Clinical Site 15 | Louisville | Kentucky | 40217 | — |
| Arcutis Biotherapeutics Clinical Site 52 | Metairie | Louisiana | 70006 | — |
| Arcutis Biotherapeutics Clinical Site 28 | Rockville | Maryland | 20850 | — |
| Arcutis Biotherapeutics Clinical Site 73 | Brighton | Massachusetts | 02135 | — |
| Arcutis Biotherapeutics Clinical Site 40 | Clinton Township | Michigan | 48038 | — |
| Arcutis Biotherapeutics Clinical Site 20 | Detroit | Michigan | 48202 | — |
| Arcutis Biotherapeutics Clinical Site 58 | Fort Gratiot | Michigan | 48059 | — |
| Arcutis Biotherapeutics Clinical Site 14 | Fridley | Minnesota | 55432 | — |
| Arcutis Biotherapeutics Clinical Site 50 | Las Vegas | Nevada | 89148 | — |
| Arcutis Biotherapeutics Clinical Site 56 | Portsmouth | New Hampshire | 03801 | — |
| Arcutis Biotherapeutics Clinical Site 55 | New York | New York | 10029 | — |
| Arcutis Biotherapeutics Clinical Site 63 | The Bronx | New York | 10462 | — |
| Arcutis Biotherapeutics Clinical Site 23 | High Point | North Carolina | 27262 | — |
| Arcutis Biotherapeutics Clinical Site 18 | Bexley | Ohio | 43209 | — |
| Arcutis Biotherapeutics Clinical Site 29 | Portland | Oregon | 97210 | — |
| Arcutis Biotherapeutics Clinical Site 27 | Pittsburgh | Pennsylvania | 15213 | — |
| Arcutis Biotherapeutics Clinical Site 76 | Charleston | South Carolina | 29407 | — |
| Arcutis Biotherapeutics Clinical Site 13 | Arlington | Texas | 76011 | — |
| Arcutis Biotherapeutics Clinical Site 11 | Austin | Texas | 78759 | — |
| Arcutis Biotherapeutics Clinical Site 41 | College Station | Texas | 77845 | — |
| Arcutis Biotherapeutics Clinical Site 25 | Houston | Texas | 77056 | — |
| Arcutis Biotherapeutics Clinical Site 26 | Pflugerville | Texas | 78660 | — |
| Arcutis Biotherapeutics Clinical Site 54 | San Antonio | Texas | 78213 | — |
| Arcutis Biotherapeutics Clinical Site 17 | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04445987, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 11, 2024 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04445987 live on ClinicalTrials.gov.